By Townhall Chicago News Staff
Chicago-based Tempus AI reported record third-quarter revenue of $411.5 million, a 23 percent increase over the same period last year, and raised its full-year 2026 revenue guidance to between $1.6 billion and $1.605 billion.
The precision medicine technology company released the results Nov. 2 in a news release. The company also announced Tuesday that it will present six abstracts at the Connective Tissue Oncology Society Annual Meeting in Seoul later this month.
“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32 percent in our oncology business and increasing momentum of 33 percent revenue growth in Data & Applications,” founder and CEO Eric Lefkofsky said in the earnings release.
Diagnostics generated $303.5 million in revenue for the quarter, representing 20 percent growth. Oncology volume growth accelerated to 32 percent. The company’s Minimal Residual Disease testing volume reached approximately 12,000 tests, up 300 percent year over year.
The Data and Applications segment generated $108.1 million, representing 33 percent growth. The Insights category within that segment grew 29 percent.
Gross profit rose 27 percent to $266.7 million. Net loss narrowed significantly to $14.9 million from $80 million in the third quarter of 2025. The improvement reflected $42.8 million in unrealized gains on marketable securities, though the quarter also included $50.8 million in stock-based compensation expense.
Adjusted EBITDA reached $25.6 million, up from $1.5 million in the same period a year earlier. The company ended the quarter with cash and marketable securities of $854.4 million.
The raised full-year revenue guidance of $1.6 billion to $1.605 billion represents approximately 25 percent annual growth. Tempus continues to expect full-year adjusted EBITDA of approximately $65 million, according to the release.
During the quarter, Tempus announced a multi-year strategic collaboration with Merck and Moderna to support the potential commercialization of an individualized neoantigen therapy. In October, it announced a strategic collaboration with Bristol Myers Squibb valued at up to $137.5 million over five years for oncology data and models, bringing total data licensing bookings above $550 million year to date.
The company also received two FDA 510(k) clearances for AI-powered cardiology products and cleared regulatory review for its pending acquisition of Personalis. The Personalis shareholder meeting to approve the acquisition is planned for Nov. 30.
On Tuesday, Tempus announced that six abstracts, including three oral presentations, were accepted for the 2026 CTOS Annual Meeting taking place Nov. 18 through 21 in Seoul. The research focuses on rare mesenchymal tumors and how advances in molecular diagnosis are unlocking new treatment options.
“In rare diseases, such as sarcoma, small patient datasets make uncovering insights exceptionally challenging, which is where Tempus’ robust dataset brings critical value,” Chief Medical Officer of Oncology Ezra Cohen, MD, said in a Nov. 11 release.
Tempus trades on the Nasdaq under the ticker symbol TEM.
